Chemokines and Chemokine Receptors Blockers as New Drugs for the Treatment of Chronic Obstructive Pulmonary Disease

2013 ◽  
Vol 20 (35) ◽  
pp. 4317-4349 ◽  
Author(s):  
G. Caramori ◽  
A. Stefano ◽  
P. Casolari ◽  
P.A. Kirkham ◽  
A. Padovani ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Chemokine Receptors ◽  
New Drugs ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

scholarly journals CD8 chemokine receptors in chronic obstructive pulmonary disease

2008 ◽  
Vol 154 (1) ◽  
pp. 56-63 ◽  
Author(s):  
L. J. C. Smyth ◽  
C. Starkey ◽  
F. S. Gordon ◽  
J. Vestbo ◽  
D. Singh
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Chemokine Receptors ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

scholarly journals Pharmacological treatment and current controversies in COPD

F1000Research ◽  
2019 ◽  
Vol 8 ◽  
pp. 1533 ◽  
Author(s):  
Mario Cazzola ◽  
Paola Rogliani ◽  
Daiana Stolz ◽  
Maria Gabriella Matera
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Lung Disease ◽  
Pulmonary Disease ◽  
Pharmacological Treatment ◽  
Obstructive Lung Disease ◽  
Chronic Obstructive Lung Disease ◽  
New Drugs ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Global Initiative

Bronchodilators, corticosteroids, and antibiotics are still key elements for treating chronic obstructive pulmonary disease in the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations and this is due in part to our current inability to discover new drugs capable of decisively influencing the course of the disease. However, in recent years, information has been produced that, if used correctly, can allow us to improve the use of the available therapies.

scholarly journals New possibilities of pharmacotherapy for chronic obstructive pulmonary disease

2018 ◽  
pp. 28-37
Author(s):  
A. I. Sinopalnikov ◽  
A. G. Romanovskikh ◽  
Yu. G. Belotserkovskaya
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Therapeutic Strategy ◽  
New Drugs ◽  
Fixed Dose ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Long Acting

The use of bronchodilators (DB) remains up to the present day the leading therapeutic strategy for the treatment of chronic obstructive pulmonary disease (COPD), in which case administration of fixed-dose combinations of long-acting bronchodilators seem the most promising. At the same time, the issues of anti-inflammatory therapy of COPD are also actively discussed, first of which is feasibility for the wide use of fixed-dose combinations of inhaled glucocorticosteroids (IHGC) with long-acting β2-agonists (LABA). Recent years are characterized by the launch of a significant number of new BDs, anti-inflammatory drugs and their combinations to the pharmaceutical market. The article considers the role and place of new drugs in the treatment of COPD having a stable course.

Sign in / Sign up

Export Citation Format

Share Document